[
  {
    "ts": null,
    "headline": "Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting",
    "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., December 01, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.",
    "url": "https://finnhub.io/api/news?id=2155f6fba5381c45ed55873eb141549ff2ffe97af480fea223c2dca338b0b350",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764592200,
      "headline": "Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting",
      "id": 137659863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., December 01, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.",
      "url": "https://finnhub.io/api/news?id=2155f6fba5381c45ed55873eb141549ff2ffe97af480fea223c2dca338b0b350"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting",
    "summary": "New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modificationCAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today annou",
    "url": "https://finnhub.io/api/news?id=471e272ae10909fd2517a21a8345ff6e77b0aa60fb68aea9e68d90d595dcf0f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764592200,
      "headline": "Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting",
      "id": 137659862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modificationCAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today annou",
      "url": "https://finnhub.io/api/news?id=471e272ae10909fd2517a21a8345ff6e77b0aa60fb68aea9e68d90d595dcf0f4"
    }
  }
]